While Harmony Biosciences HRMY may not be a typical cannabis stock involved in cultivation, processing, or sales of marijuana products, it is among the few companies evaluating an investigational cannabidiol...
Jazz Pharmaceuticals JAZZ and Harmony Biosciences HRMY have emerged as notable players in the neuroscience space, especially in the sleep disorder segment.Jazz Pharmaceuticals markets multiple neuroscience...
Shares of Harmony Biosciences HRMY have lost 10.8% in the past six months compared with the industry’s decline of 9.7%. The stock has also underperformed the S&P 500 index during this timeframe.The stock...
HRMY earnings call for the period ending December 31, 2024.
Axsome Therapeutics AXSM incurred an adjusted loss of 96 cents per share in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 90 cents. The company had incurred a loss of...
Agios Pharmaceuticals AGIO incurred a loss of $1.74 per share in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.73. In the year-ago quarter, the company had reported...
Alkermes plc ALKS reported adjusted earnings from continuing operations of $1.04 per share for fourth-quarter 2024, which beat the Zacks Consensus Estimate of 81 cents. The company had reported adjusted...
Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.BEAM’s...
For Immediate ReleaseChicago, IL – January 24, 2025 – Stocks in this week’s article are — Harmony Biosciences HRMY, Ingevity Corp. NGVT, Gulfport Energy GPOR and Pitney Bowes PBI.4 High Earnings...
The favorable December inflation reading has eased concerns about the Federal Reserve’s ability to justify rate cuts in 2025. Adding to the positive sentiment is the strong start to the fourth-quarter...